Skip to main content

Correction to: Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation

The Original Article was published on 06 January 2021

Correction to: Cancer Cell Int (2021) 21:24 https://doi.org/10.1186/s12935-020-01728-4

Following the publication of the original article [1], we were notified of a mistake in Fig. 5c.

Figure 5c contains the representative images of cell invasion, while Fig. 5a contains the representative images of cell migration. Figure 5a and 5c were both taken at the high magnification (10×). By mistake, the images in the cell migration folder were used in the Fig. 5c. Therefore, Fig. 5a and the statistical histograms in Fig. 5b and 5d are correct, but all the images in Fig. 5c were incorrect.

The conclusions made are not influenced by the mistake of Fig. 5c, because the statistical analysis was performed based on the images of cell migration and invasion taken at the low magnification (4×).

The original article has been corrected to reflect these changes.

Reference

  1. 1.

    Zhao H, Wu C, Zhou X, Diao P, Xu Y, Liu J, Wang J, Huang X, Liu W, Chen Z, Huang G, Li W. Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation. Cancer Cell Int. 2021;21:24. https://doi.org/10.1186/s12935-020-01728-4.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Wei‑ping Li.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhao, H., Wu, C., Zhou, X. et al. Correction to: Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation. Cancer Cell Int 21, 403 (2021). https://doi.org/10.1186/s12935-021-02028-1

Download citation